Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function

Critical Reviews in Clinical Laboratory Sciences

Volumn 33, Issue 5, 1996, Pages 357-421

  Muszbek, László ^a   Ádány, Róza ^a   Mikkola, Hanna ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Calcium; Factor XIII; Fibrin; Fibrinogen; Fibrinolysis; Fibronectin; Macrophages; Monocytes; Platelets; Pregnancy; Thrombin; Transglutaminase; Wound healing; 2 antiplasmin

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; CALCIUM ION; CONTRACTILE PROTEIN; FIBRIN; FIBRINOGEN; PLASMIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; THROMBIN;

BLOOD CLOTTING; BONE MARROW CELL; CALCIUM CELL LEVEL; CHROMOSOME 1Q; CHROMOSOME 6P; CROSS LINKING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBUNIT; ENZYME SYNTHESIS; FIBRINOLYSIS; GENE LOCATION; HEMOSTASIS; LIVER; LIVER CELL; MACROPHAGE; MEGAKARYOCYTE; MONOCYTE; PLASMA; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; TISSUE REPAIR; WOUND HEALING;

EID: 0029847710     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408369609084691     Document Type: Review

References (328)

1. Barkan G, Gaspar A. Zur Frage der Reversibilität der Fibringerinnung II. Biochem Z 1923; 139: 291-301.
2. Robbins KC. A study on the conversion of fibrinogen to fibrin. Am J Physiol 1944; 142: 581-8.
3. Laki K, Lóránd L. On the solubility of fibrin clots. Science 1948; 108: 280.
4. Lóránd L. A study on the solubility of fibrin clots in urea. Acta Physiol Acad Sci Hung 1948; 1: 192-6.
5. Lóránd L. Fibrin clots. Some properties of the "serum factor." Nature (London) 1950; 166: 694-6.
6. Loewy AG, Veneziale C Forman, M. Purification of the factor involved in formation of urea-insoluble fibrin. Biochim Biophys Acta 1957; 26: 670-1.
7. Loewy AG, Dunathan K, Kriel K, Wolfinger J. et al. Fibrinase. I. Purification of substrate and enzyme. J Biol Chem 1961; 236: 2625-33.
8. Loewy AG, Dahlberg A, Dunathan K, et al. Fibrinase. II. Some physical properties. J Biol Chem 1961; 236: 2634-43.
9. Loewy AG, Dunathan K, Gallant JA, et al. Fibrinase. III. Some enzymatic properties. J Biol Chem 1961; 236: 2644-7.
10. Loewy AG, Gallant JA Dunathan K. Fibrinase. IV. Effect on fibrin solubility. J Biol Chem 1961; 236: 2648-55.
11. Duckert F, Jung E Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-86.
12. Folk JA, Finlayson JS. The epsilon(γ-glutamyl)lysine cross-link and the catalytic role of transglutaminases. Adv Protein Chem 1977; 31: I-133.
13. Lóránd L, Losowsky MS Miloszewski KJM. Human factor XIII: fibrin-stabilizing factor. Prog Haemost Thromb 1980; 5: 245-90.
14. Folk JE. Mechanism and basis for specifity of transglutaminase catalyzed epsilon(gamma glutamyl)lysine bond formation. Adv Enzymol 1983; 54: 1-56.
15. Muszbek L, Laki K. Interaction of thrombin with proteins other than fibrinogen (thrombin susceptible bonds). Activation of factor XIII. In: Machovich R, ed. The thrombin. Pp. 83-102. Boca Raton, FL: CRC Press, 1984.
16. Lóránd L. Activation of blood coagulation factor XIII. Ann NY Acad Sci 1986; 485: 144-58.
17. McDonagh J. Structure and function of factor XIII. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Haemostasis and thrombosis. Pp. 164-73. Philadelphia: Lippincott, 1982.
18. Miloszewski KJA, Losowsky MS. Fibrin stabilization and factor XIII deficiency. In: Francis JL, ed. Fibrinogen, fibrin stabilisation and fibrinolysis. Pp. 175-202. Chichester: Ellis Horwood, 1988.
19. Ichinose A, Hendrickson LE, Fujikawa K, et al. Amino acid sequence of the a subunit of human factor XIII. Biochemistry 1986; 25: 6900-6.
20. Ichinose A, McMullen B, Fujikawa K, et al. Amino acid sequence of the b subunit of human factor XIII, a protein composed of ten repetitive segments. Biochemistry 1986; 25: 4633-38.
21. Grundmann U, Amann E, Zettlmeissl G, et al. Characterization of cDNA coding for human factor XIIIa. Proc Natl Acad Sci USA 1986; 83: 8024-8.
22. Takahashi N, Takahashi Y Putnam FW. Primary structure of blood coagulation XIIIa (fibrinoligase, transglutaminase) from human placenta. Proc Natl Acad Sci USA 1986; 83: 8019-23.
23. Ichinose A, Davie E. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA 1988; 85: 5829-33.
24. Bohn H. The human fibrin-stabilizing factor. Mol Cell Biochem 1978; 20: 67-75.
25. Board PG, Webb GC, McKee J, et al. Localization of the coagulation factor XIII A-subunit gene (F13A) to chromosome bands 6p24-25. Cytogenet Cell Genet 1988; 48: 25-7.
26. Korsgren C, Cohen CM. Organization of the gene for human erythrocyte membrane protein 4.2: structural similarities with the gene for the a subunit of factor XIII. Proc Natl Acad Sci USA 1991; 88: 4840-44.
27. Aeschlimann D, Paulsson M. Transglutaminases: protein cross-linking reactions in tissues and body fluids. Thrombos Haemostas 1994; 71: 402-15.
28. Board PG, Pierce K Coggan M. Expression of functional coagulation factor XIII in Escherichia coli. Thromb Haemost 1990; 63: 235-40.
29. Bröker M, Bäuml O. New expression vectors for the fission yeast Schizosaccharomyces pombe. FEBS Lett 1989; 248: 105-10.
30. Jagadeeswaran P, Haas P. Synthesis of human coagulation factor XIII in yeast. Gene 1990; 86: 279-83.
31. Bishop PD, Teller DC, Smith RA, et al. Expresion, purification and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 1990; 29: 1861-9.
32. Rodriguez de Cordoba S, Rey-Campos S, Dykes DD, et al. Coagulation Factor XIIIB subunit is encoded by a gene linked to the regulator of complement activation (RCA) gene cluster in man. Imnnmogenetics 1988; 28: 452-4.
33. Kompf J, Luckenbach C, Kloor D, et al. Linkage analyses of human peptidase C (PEPC), human factor H (HF), and coagulation factor XIIIB (F13B). Hum Genet 1989; 83: 97-8.
34. Rey-Campos J, Baeza-Sanz D Rodriguez de Cordoba S. Physical linkage of the genes coding for complement factor H and coagulation factor XIII B subunit. Genomics 1990; 7: 644-6.
35. Griffith LR, Board PG, Zwi MB, et al. The B subunit of coagulation factor XIII is linked to renin, and the Duffy blood group to alpha-spectrin on human chromosome 1. Hum Hered 1989; 39: 107-9.
36. Webb GC, Coggan M, Ichinose A, et al. Localization of coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment length polymorphism at the locus. Hum Genet 1989; 81: 157-60.
37. Ichinose A, Bottenus RE Davie EW. Structure of transglutaminases. J Biol Chem 1990; 265: 13411-14.
38. Nonaka M, Matsuda Y, Shiroishi T, et al. Molecular cloning of the b subunit of mouse coagulation factor XIII and assignment of the gene to chromosome 1: close evolutionary relationship to complement factor H. Genomics 1993; 15: 535-42.
39. Bottenus R, Ichinose A Davie E. Nucleotide sequence of the gene for the b subunit of human factor XIII. Biochemistry 1990; 29: 11195-209.
40. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
41. Patthy L. Detecting homology of distantly related proteins with consensus sequence. J Mol Biol 1987; 198: 567-77.
42. Board PG. Genetic polymorphism of the A subunit of human coagulation factor XIII. Am J Hum Genet 1979; 31:116-24.
43. Board PG. Genetic polymorphism of the B subunit of human coagulation factor XIII. Am J Hum Genet 1980; 32: 348-53.
44. Board PG, Coggan M. Polymorphism of the A subunit of coagulation Factor XIII in the pacific region. Description of new halotypes. Hum Genet 1981; 59:135-6.
45. Nishigaki T, Omoto K Juji T. Genetic polymorphism of the A subunit of human coagulation factor XIII in Japanese. Jpn J Hum Genet 1981; 26: 237-41.
46. Castle M, Board PG. An extended survey of the genetic polymorphism at the human coagulation factor XIIIA subunit structural locus. Hum Hered 1981; 35: 101-6.
47. Sebatan IM. A new method for FXIIIA genetic variants determination using isoelectric focusing in 1 M urea. Evidence for three structural gene loci, FXIIIA1, FXIIIA2 and FXIIIA3. Hum Genet 1988; 81: 95-7.
48. Suzuki K, Matsui K, Ito S, et al. Polymorphism of the A subunit of coagulation factor XIII: evidence for subtypes of the FXIIIA*1 and FXIIIA*2 alleles. Am J Hum Genet 1988; 43: 170-4.
49. Prata MJ, Amorim A. Formal and population genetics of F13A and FUCA1 polymorphism in northern Portugal. Hum Hered 1990; 40: 45-8.
50. Scacchi R, Corbo RM, Mulas G, et al. Genetic polymorphism of the A and B subunits of human coagulation factor XIII in mainland Italy and Sardinia: description of a new FXIIIA variant allele. Electrophoresis 1991; 12: 667-70.
51. Nishigaki T, Omoto K. Genetic polymorphism of the B subunit of human coagulation factor XIII in Japanese. Jpn J Hum Gen 1982; 27: 265-70.
52. Board PG. Genetic heterogeneity of the B subunit of coagulation factor XIII: resolution of type 2. Ann Hum Genet 1984; 48: 223-8.
53. Miller SA, Dykes DD Polesky HF. Gene frequency distribution of the B subunit of factor XIII (FXIIIB) in Minnesota whites, blacks, and amerindians. Electrophoresis 1985; 6: 399-401.
54. Kamboh MI, Ferrell RE. Genetic studies of low abundance human plasma proteins. II. Population genetics of coagulation factor XIIIB. Am J Hum Genet 1986; 39: 817-25.
55. Dykes DD, Polesky MF. The use of the serum protein factor XIIIB (FXIIIB) in parentage testing. Am J Clin Pathol 1987; 88: 627-30.
56. Leifheit HJ, Cleve H. Analysis of the genetic polymorphism of coagulation factor XIIIB (FXIIIB) by isoelectric focusing. Electrophoresis 1988; 9: 426-9.
57. Kamboh MI, Ferrell RE. Genetic studies of low-abundance human plasma proteins. X. Coagulation factor XIIIB variants in blacks. Electrophoresis 1989; 10: 53-7.
58. Tela M, Scheffran W. Der Faktor 13 B (FSF)-Polymorphismus in schweizerischen Populationen, mit Betrachtungen über europäische Häufigkeitesgradienten. Anthropol Anz 1991; 49: 129-36.
59. Nevo S, Cleve H, Koller A, et al. Serum protein polymorphism in Arab moslems and Druze of Israel. Hum Biol 1992; 64: 587-603.
60. Cleve H, Koller A, Patutschnick W, et al. Genetic serum protein polymorphism in Jordanian Arabs: a pilot study of the systems AHSG, BF, F XIII B, GC, PI, PLG and TF. Gene Geogr 1992; 6: 31-40.
61. Saha N, Tay JS, Low PS, et al. Population genetics of coagulation factor XIIIB in three ethnic groups of Singapore. Ann Hum Biol 1992; 19: 277-83.
62. Chen LZ, Easteal S, Board PG, et al. Genetic affinities of oceanic populations based on RFLP and halotype analysis of genetic loci on three chromosomes. Hum Biol 1992; 64: 1-15.
63. Komatsu N, Kido A, Kimura Y, et al. Polymorphism of coagulation factor XIII B subunit: further occurrence of FXIIIB*15 in Japanese and phenotyping in bloodstains. Int J Legal Med 1992; 317-9.
64. Cameselle FD, Caeiro B Riveiro A. An alternative modality for the immunodetection of the molecular phenotypes of coagulation factor XIIIB. Hum Hered 1993; 43: 257-60.
65. Mizutani K, Nishimukai H, Yasugi T, et al. Polymorphism of serum proteins in Japanese patients with vascular disease. I. Factor XIIIB, plasminogen and complement types in primary varicose veins. Hum Hered 1991; 41: 270-5.
66. Board PG, Chapple R Coggan M. Halotypes of the coagulation Factor XIIIA subunit locus in normal and deficient subjects. Am J Hum Genet 1988; 42:712-7.
67. Zoghbi HY, Daiger SP, McCall A, et al. Extensive DNA polymorphism at the factor XIIIa (F13A) locus and linkage to HLA. Am J Hum Genet 1988; 42: 877-83.
68. Board PG, Losowsky MS Miloszewski KJA. Factor XIII: Inherited and acquired deficiency. Blood Rev 1993; 7: 229-42.
69. Polymeropoulos MH, Rath DS, Xiao H, et al. Tetranucleotide repeat polymorphism at the human coagulation factor XIII A subunit gene (F13A1). Nucleic Acids Res 1991; 19: 4306.
70. Nishimura DY, Murray JC. A tetranucleotide repeat for the F13B locus. Nucleic Acids Res 1992; 20: 1167.
71. Carrell NA, Erickson HP McDonagh, J. Electron microscopy and hydrodynamic properties of factor XIII subunits. J Biol Chem 1989; 264: 551-6.
72. Bohn H, Schwick HG. Isolierung and Characterisierung eines fibrinstabilierenden Faktors aus menschlichen Plazenten. Arzneim Forsch 1971; 21: 1432-9.
73. Hilgenfeld R, Liesum A, Storm R, et al. Crystallization of blood coagulation factor XIII by an automated procedure. FEBS Lett 1990; 265: 110-2.
74. Bishop PD, Lasser GW, Le Trong I, et al. Human recombinant factor XIII from Saccharomyces cerevisiae. Crystallization and preliminary X-ray data. J Biol Chem 1990; 265: 13888-9.
75. Yee VC, Pedersen L, Le Trong I, et al. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-300.
76. Pedersen LC, Yee VC, Bishop PD, et al. Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules. Protein Sci 1994; 3: 1131-5.
77. Yorifuji H, Anderson K, Lynch GW, et al. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-50.
78. Henriksson P, Hedner U, Nilsson IM, et al. Fibrin-stabilizing factor (Factor XIII) in the fetus and the newborn infant. Pediatr Res 1974; 8: 789-91.
79. Radek JT, Jeong JM, Wilson J, et al. Association of A subunits of recombinant placental factor XIII with the native carrier B subunits from human plasma. Biochemistry 1993; 32: 3527-34.
80. Barbui K, Rodeghiero F Dini E. Subunit A and S inheritance in four families with congenital Factor XIII deficiency. Br J Haematol 1978; 38: 267-71.
81. Skrzynia C, Reisner H McDonagh J. Characterization of the catalytic subunit of factor XIII by radioimmunoassay. Blood 1982; 60: 1089-95.
82. Krøll J. The subunit composition of factor XIII proteins in normal and factor XIII deficient plasma and serum analyzed by line immunoelectrophoresis. Clin Chim Acta 1989; 179: 279-84.
83. Rodeghiero F, Morbin M Barbui T. Subunit A of factor XIII regulates subunit B plasma concentration. Thromb Haemost 1981; 46: 621-2.
84. Miloszewski KJM, Losowsky MS. The half life of factor XIII in vivo. Br J Haematol 1978; 38: 267-71.
85. Fear JD, Miloszewski KJA Losowsky MS. The half-life of Factor XIII in the management of inherited deficiency. Thromb Haemost 1983; 49: 102-5.
86. Rodeghiero F, Tosetto A, Di Bona E, et al. Clinical pharmacokinetics of placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991; 36: 30-4.
87. Saito M, Asakura H, Yoshida T, et al. A familial factor XIII subunit B deficiency. Br J Haematol 1990; 74: 290-4.
88. Greenberg CS, Shuman MA. The zymogen form of blood coagulation factor XIII binds specifically to fibrinogen. J Biol Chem 1982; 257: 6096-101.
89. Greenberg CS, Dobson JV Miraglia CC. Regulation of plasma factor XIII binding to fibrin in vitro. Blood 1985; 66: 1028-34.
90. a). Calcium ion regulatory aspect. Biochemistry 1981; 20: 3770-8.
91. Lóránd L, Jeong JM, Radek JT, et al. Human plasma factor XIII: subunit interactions and activation of zymogen. Methods Enzymol 1993; 222: 22-35.
92. Mary A, Achyuthan KE Greenberg CS. Factor XIII binds to the Aα-and Bβ-chains in the domain of fibrinogen: an immunoblotting study. Biochem Biophys Res Commun 1987; 147: 608-14.
93. Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-9.
94. Naski MC, Lóránd L Shafer JA. Characterization of the kinetic pathway for fibrin promotion of α-thrombin catalyzed activation of plasma factor XIII. Biochemistry 1991; 30: 934-41.
95. Greenberg CS, Enghild JJ, Mary A, et al. Isolation of a fibrin-binding fragment from blood coagulation factor XIII capable of cross-linking fibrin(ogen). Biochem J 1988; 256: 1013-9.
96. Buluk K. An unknown function of blood platelets. Pol Tyg Lek 1955; 10: 191.
97. Lüscher EF. Ein fibrinstabilisierender Faktor aus Thrombozyten. Schweiz Med Wochenschr 1957; 87: 1220-1.
98. Bohn H. Isolierung und Characterisierung des fibrinstabilisierenden Faktors aus menschlichen Thrombozyten. Thromb Diath Haemorrh 1970; 23: 455-68.
99. Puszkin EG, Raghuraman V. Catalytic properties of a calmodulin-regulated transglutaminase from human platelets and chicken gizzard. J Biol Chem 1985; 260: 16012-20.
100. Muszbek L, Ádány R, Kávai M, et al. Monocytes of patients congenially deficient in plasma factor XIII lack factor XIII subunit A antigen and transglutaminase activity. Thromb Haemost 1988; 59: 231-5.
101. Boda Z, Pfliegler G, Muszbek L, et al. Congenital factor XIII deficiency with multiple benign breast tumors and successful pregnancy with substitutive therapy. Haemostasis 1989; 19: 348-52.
102. Kiesselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann NY Acad Sci 1972; 202: 318-28.
103. Ádány R, Kiss A Muszbek L. Factor XIII: a marker of mono-, and megakaryocytopoesis. Br J Haematol 1987; 67: 167-72.
104. McDonagh J, McDonagh RP, Delage JM, et al. Factor XIII in human plasma and platelets. J Clin Invest 1969; 48: 940-6.
105. Marx G, Korner G, Mou X, et al. Packaging zinc, fibrinogen and factor XIII in platelet α-granules. J Cell Physiol 1993; 156: 437-42.
106. Lopaciuk S, Lovette KM, McDonagh J, et al. Subcellular distribution of fibrinogen and factor XIII in human blood platelets. Thromb Res 1974; 8: 453-65.
107. Broekman MJ, Handin RJ Cohen P. Distribution of fibrinogen and platelet factor 4 and XIII in subcellular fractions of human platelets. Br J Haematol 1975; 31: 51-5.
108. Takagi J, Kasahara K, Sekiya F, et al. Subunit B of factor XIII is present in bovine platelets. Thromb Res 1988; 50: 767-74.
109. Muszbek L, Ádány R, Szegedi G, et al. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10.
110. Ádány R, Belkin A, Vasilevskaya T, et al. Identification of blood coagulation factor XIII in human peritoneal macrophages. Eur J Cell Biol 1985; 38: 171-3.
111. Henriksson P, Becker S, Lynch G, et al. Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34.
112. Ádány R, Kappelmayer J, Muszbek L. Expression of factor XIII subunit A in different types of human macrophages. Adv Biosci 1987; 66: 323-33.
113. Kradin RL, Lynch GW, Kurnick JT, et al. Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages. Blood 1987; 69: 778-85.
114. Ádány R, Nemes Z Muszbek L. Characterization of factor XIII containing macrophages in lymph nodes with Hodgkin's disease. Br J Cancer 1987; 55: 421-6.
115. Ádány R, Nemes Z, Thomázy V, et al. Identification of factor XIII in macrophages invading lymph nodes with Hodgkin's disease. In: Muszbek L, ed. Haemostasis and cancer. Pp. 125-34. Boca Raton, FL: CRC Press, 1987.
116. Turnock K, Bulmer JN Gray C. Phenotypic characterization of macrophage subpopulations and localization of factor XIII in the stromal cells of carcinomas. Histochem J 1990; 22: 661-6.
117. Nemes Z, Thomázy V, Ádány R, et al. Identification of histiocytic reticulum cells by the immunohistochemical demonstration of factor XIII (F-XIIIa) in human lymph nodes. J Pathol 1986; 149: 121-32.
118. Nemes Z, Ádány R Thomázy V. Selective visualization of human dendritic reticulum cells in reactive lymphoid follicles by immunohistochemical demonstration of the subunit A of factor XIII (F-XIIIa). Virchows Arch (Cell Pathol) 1987; 52: 453-66.
119. Ádány R, Muszbek L. Cells containing factor XIII subunit a in benign and soft tissue tumors. Histopathology 1987; 11: 1341-2.
120. Ádány R, Glukhova M, Kabakov AY, et al. Characterization of connective tissue cells containing factor XIII subunit a. J Clin Pathol 1988; 41: 49-56.
121. Estrada JA, Piérard GE. Factor XIIIa-positive dendrocytes and the dermal vascular unit. Dermatologica 1990; 180: 51-3.
122. Morganroth GS, Chan LS, Weinstein GD, et al. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells and FXIIIa+ perivascular dendritic cells. J Invest Dermatol 1991; 96: 333-40.
123. Nemes Z. Differentiation markers in hemangiopericytoma. Cancer 1992; 69: 133-40.
124. Cerio R, Spaull J Wilson JE. Identification of factor XIIIa in cutaneous tissue. Histopathology 1988; 13: 362-3.
125. Ádány R. Identification of factor XIIIa in cutaneous tissue. Reply. Histopathology 1988; 13: 363-4.
126. Cerio R, Griffiths CE, Cooper KD, et al. Characterisation of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Brit J Dermatol 1989; 121: 421-31.
127. Weisberg LJ, Shiu DT, Conkling PR, et al. Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain. Blood 1987; 70: 579-82.
128. Ádány R, Polgár E Antal M. Three different cell types can synthesize factor XIII subunit A in human liver. In: Fourth International Conference on Transglutaminases and Protein Cross-linking Reactions. Abstract Book, 1994.
129. Berntorp E, Seiving B Stenberg P. Characterization of transglutaminase in normal and malignant human leucocytes. Scand J Haematol 1985; 34: 71-7.
130. Sieving B, Ohlsson K, Linder C, et al. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur J Haematol 1991; 46: 263-71.
131. Conkling PR, Achyuthan KE, Greenberg CS, et al. Human mononuclear phagocyte transglutaminase activity cross-links fibrin. Thromb Res 1989; 55: 57-68.
132. Muszbek L, Polgár J Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69: 282-5.
133. Muszbek L, Haramura G Polgár J. Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost 1995; 74: 702-5.
134. Mehta K, Lopez-Berenstein G, Moore WT, et al. Interferon-gamma requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes. J Immunol 1985; 134: 2053-6.
135. Chung SI. Comparative studies on tissue transglutaminase and factor XIII. Ann NY Acad Sci 1972; 202: 240-55.
136. Kappelmayer J, Bacskó G, Kelemen E, et al. Onset and distribution of FXIII-containing cells in the mesenchyme of chorionic villi during early phase of human placentation. Placenta 1994; 15: 613-23.
137. Ádány R, Muszbek L. Immunohistochemical detection of factor XIII subunit a in hystiocytes of human uterus. Histochemistry 1989; 91: 169-74.
138. Fear JD, Jackson P, Gray C, et al. Localization of factor XIII in human tissues using an immunoperoxidase technique. J Clin Pathol 1984; 37: 560-3.
139. Reid MB, Gray C, Fear JD, et al. Immunohistochemical demonstration of factors FXIIIa and XIIIs in reactive and neoplastic fibroblastic and fibrohistiocytic lesions. Histopathology 1986; 10: 1171-8.
140. Nemeth AJ, Penneys NS. Factor XIIIa is expressed by fibroblasts in fibrovascular tumors. J Cutan Pathol 1989; 16: 266-71.
141. Nemes Z, Thomázy V. Diagnostic significance of histiocyte-related markers in malignant histiocytosis and true histiocytic lymphoma. Cancer 1988; 62: 1970-80.
142. Nemes Z, Thomázy V. Factor XIIIa and the classic histiocytic markers in malignant fibrous histiocytoma: a comparative immunohistochemical study. Hum Pathol 1988; 19: 822-9.
143. Cerio R, Spaull J Jones EW. Histiocytoma cutis, a tumour of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol 1989; 120: 197-206.
144. Delabie J, De Wolf-Peeters C, Morren M, et al. Histiocytes in Sweet's syndrome. Br J Dermatol 1991; 124: 348-53.
145. Nemeth AJ, Penneys NS Bernstein HB. Fibrous papule: a tumor of fibrohistiocytic cells that contain factor XIIIa. J Am Acad Dermatol 1988; 19:1102-6.
146. Nickoloff BJ, Griffiths CEM. Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi's sarcomas. Science 1989; 243: 1736-7.
147. Walls WD, Losowsky MS. Plasma fibrin stabilizing factor (FSF) activity in normal subjects and patients with chronic liver disease. Thromb Diath Haemorrh 1969; 21: 134-43.
148. Biland L, Duckert F, Prisender S, et al. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost 1979; 39: 646-56.
149. Gybryelewicz A, Bielawiec M. Fibrin stabilization, factor XIII transamidase activity and subunits "a" and "b" concentration in plasma of patients with liver cirrhosis. Folia Haematol 1986; 113: 539-44.
150. Yoshioka K, Miyata H, Uraoka Y, et al. Plasma factor XIII levels in children with renal disease. Nephron 1981; 27: 19-24.
151. Cucuianu MP, Miloszewski K, Porutiu D, et al. Plasma factor XIII and platelet factor XIII in hyperlipaemia. Thromb Haemost 1976; 36: 542-50.
152. Ikematsu S. An approach to the metabolism of factor XIII. Acta Haematol Jpn 1981; 44: 1499-505.
153. Miloszewski KJA, Losowsky MS. Clinical consequences of inherited and acquired factor XIII deficiency. In: Egbring R, Klingemann HD, eds. Factor XIII and fibronectin - new clinical and biological approaches. Pp. 31-9. Marburg/Lahn: Medizinische Verlagsgesellschaft mbH, 1983.
154. Trimble CL, Gray MH McNutt NS. The distribution of factor XIIIa-positive cells in the human fetus and placenta. Virchows Arch A 1992; 420: 513-8.
155. Derrick EK, Barker JN, Khan A, et al. The tissue distribution of factor XIIIa positive cells. Histopathology 1993; 22: 157-62.
156. Nagy JA, Henriksson P McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 1272-9.
157. Wölpl A, Lattke H, Board PG, et al. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation 1987; 43: 151-3.
158. Poon MC, Russel, JA, Low S, et al. Hemopoietic origin of factor XIII subunits in platelets, monocytes and plasma. Evidence from bone marrow transplantation studies. J Clin Invest 1989; 84: 787-92.
159. Janus TJ, Lewis SD, Lóránd L, et al. A promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 1983; 22: 6269-72.
160. Lewis SD, Janus TJ, Lóránd L, et al. Regulation of formation of factor XIIIa by its fibrin substrates. Biochemistry 1985; 24: 6772-7.
161. Greenberg CS, Miraglia CC. The effect of fibrin polymers on thrombin catalyzed plasma factor XIII formation. Blood 1985; 66: 466-9.
162. Greenberg CS, Miraglia CC, Rickles FR, et al. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. Arch Biochem Biophys 1988; 262: 142-8.
163. Greenberg CS, Achyuthan KE, Rajagopalan S, et al. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. J Clin Invest 1985; 75: 1463-70.
164. Chung SI, Lewis MS Folk JE, Relationship of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structure. J Biol Chem 1974; 249: 940-50.
165. Greenberg CS, Achyuthan KE Fenton JW. Factor XIIIa formation promoted by complexing of α-thrombin, fibrin and plasma factor XIII. Blood 1987; 69: 867-71.
166. Hornyak TJ, Bishop PD Shafer JA. α-Thrombin-catalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIIIa activity. Biochemistry 1989; 28: 7326-32.
167. Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry 1991; 30: 6175-82.
168. Polgár J, Lénárt I, Muszbek L, et al. Thrombomodulin inhibits the activation of factor XIII by thrombin. Thromb Res 1986; 43: 585-90.
169. Mary A, Achyuthan KE Greenberg CS. b-Chains prevent the proteolytic inactivation of the a-chains of plasma factor XIII. Biochim Biophys Acta 1988; 966: 328-35.
170. Curtis CG, Brown KL, Credo RB, et al. Calcium-dependent unmasking of active center cystein during activation of fibrin stabilizing factor. Biochemistry 1974; 13: 3774-80.
171. Achyuthan KE, Mary A Greenberg CS. Tb(III)-ion-binding-induced conformational changes in platelet factor XIII. Biochem J 1989; 257: 331-8.
172. De Backer-Royer C, Traoré F Meunier JC. Purification and properties of factor XIII from human placenta. Int J Biochem 1992; 24: 91-7.
173. 2+-related regulatory function of fibrinogen. Proc Natl Acad Sci USA 1978; 75: 675-82.
174. Cook RD. Calcium-induced dissociation of human plasma factor XIII and the appearance of catalytic activity. Biochem J 1974; 141: 683-91.
175. Seelig GF, Folk JE. Half-of-the-sites and all-of-the-sites reactivity in human plasma blood coagulation factor XIIIa. J Biol Chem 1980; 255: 9589-93.
176. Barry ELR, Mosher FD. Binding and degradation of blood coagulation factor XIII by cultured fibroblasts. J Biol Chem 1990; 265: 9302-7.
177. Greenberg CS, Shuman MA. Specific binding of blood coagulation factor XIII3 to thrombin-stimulated platelets. J Biol Chem 1984; 259: 14721-27.
178. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 83: 1006-16.
179. Lóránd L, Credo RB Janus TJ. Factor XIII (fibrin stabilizing factor). Methods Enzymol 1981; 80: 333-41.
180. Polgár J, Hidasi V Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem J 1990; 267: 557-60.
181. 2+ dependent cross-linking process in human platelets. Biochim Biophys Acta 1981; 676: 137-47.
182. Cohen I, Lim CT, Kahn DR, et al. Disulfide-linked and transglutaminase-catalyzed protein assemblies in platelets. Blood 1985; 66: 143-51.
183. Hársfalvi J, Fésüs L, Tarcsa E, et al. The presence of a covalent cross-linked matrix in human platelets. Biochim Biophys Acta 1991; 1073: 268-74.
184. Ando Y, Imamura S, Yamagata Y, et al. Platelet factor XIII is activated by calpain. Biochem Biophys Res Commun 1987; 144: 484-90.
185. Lynch GW, Pfueller SL. Thrombin-independent activation of platelet factor XIII by endogenous platelet acid protease. Thromb Haemost 1988; 59: 372-7.
186. Lóránd L, Conrad SM. Transglutaminases. Mol Cell Biochem 1984; 58: 9-35.
187. Parameswaran KN, Lóránd L. New thioester substrates for fibrinoligase (coagulation factor XIIIa) and for transglutaminases. Transfer of fluorescently labeled acyl group to amines and alcohols. Biochemistry 1981; 20: 3703-11.
188. Micanovic R, Procyk R, Lin W, et al. Role of histidine 373 in the catalytic activity of coagulation factor XIII. J Biol Chem 1994; 269: 9190-4.
189. Gorman JJ, Folk JE. Structural features of glutamine substrates for transglutaminases: specificities of human plasma factor XIIIa and the guinea pig liver enzyme. J Biol Chem 1981; 256: 2712-5.
190. Gorman JJ, Folk JE. Structural features of glutamine substrates for transglutaminases: role of extended interactions in the specificity of human plasma factor XIIIa and the guinea pig liver enzyme. J Biol Chem 1984; 259: 9007-10.
191. Parameswaran KN, Velasco PT, Wilson J, et al. Labeling of ε-lysine cross-linking sites in proteins with peptide substrates of factor XIIIa and transglutaminase. Proc Natl Acad Sci USA 1990; 87: 8472-5.
192. Shafer JA, Higgins DL. Human fibrinogen. CRC Crit Rev Clin Lab Sci 1988; 26: 1-41.
193. Mosesson MW. The assembly and structure of the fibrin clot. Nouv Rev Fr Hematol 1992; 34: 11-6.
194. Mosesson MW, Siebenblist KR, Amrani DL, et al. Proc Natl Acad Sci USA 1989; 86: 1113-7.
195. Shainoff JR, Urbanic DA DiBello PM. Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. J Biol Chem 1991; 266: 6429-37.
196. Grøn B, Filion-Myklebust C, Bennick A, et al. Early cross-linked fibrin in human plasma contains α-polymers with intact fibrinopeptide A. Blood Coag Fibrinol 1992; 3: 731-6.
197. Lóránd L, Ong HH. Labeling of amine-acceptor cross-linking sites of fibrin by transpeptidation. Biochemistry 1966; 5: 1747-53.
198. Lóránd L. Physiological cross-linking of fibrin. Thromb Diath Haemorrh Suppl 1970; 39: 75-102.
199. Kanaide D, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). J Lab Clin Med 1975; 85: 574-97.
200. Fowler WE, Erickson HP, Hantgan RR, et al. Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. Science 1981; 211: 287-9.
201. Blombäck B, Procyk R, Adamson L, et al. FXIII induced gelation of human fibrinogen -an alternative thiol enhanced, thrombin independent pathway. Thromb Res 1985; 37: 613-28.
202. Dardik BN, Shainoff JR. Cross-linking of monomeric fibrin by factor XIIIa. Thromb Haemost 1979; 42: 864-72.
203. Dyr JE, Blombäck B, Hessel B, et al. Conversion of fibrinogen to fibrin by preferential release of fibrinopeptide B. Biochim Biophys Acta 1989; 990: 18-24.
204. Francis RT, McDonagh J Mann KG. Factor Visa substrate for the transamidase factor XIIIa. J Biol Chem 1986; 261: 9787-92.
205. Huh MM, Schick B, Schick PK, et al. Blood 1986; 66: 336a.
206. Huh MM, Schick B, Schick PK, et al. Covalent cross-linking of human coagulation factor V by activated factor XIII from guinea pig megakaryocytes and human plasma. Blood 1988; 71: 1693-702.
207. Aoki N, Harpel PL. Inhibitors of the fibrinolytic enzyme system. Sem Thromb Haemost 1984; 10: 24-41.
208. 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
209. 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280-6.
210. 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 1982; 706: 158-64.
211. 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. J Clin Invest 1986; 77: 1006-13.
212. 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
213. 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
214. Jansen PH, Lóránd L, Ebbesen P, et al. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Eur J Biochem 1993; 214: 141-6.
215. Borth W, Chang V, Bishop P, et al. Lipoprotein (a) is a substrate for FXIIIa and tissue transglutaminase. J Biol Chem 1991; 266: 18149-53.
216. Mosher DF. Cross-linking of cold-insoluble globulin by fibrin stabilizing factor. J Biol Chem 1975; 250: 6614-21.
217. Williams EC, Janmey PA, Johnson RB, et al. Fibronectin. Effect of disulfide bond reaction on its physical and functional properties. J Biol Chem 1983; 258: 6595-601.
218. Okada M, Blombäck B, Chang MD, et al. Fibronectin and fibrin gel structure. J Biol Chem 1985; 260: 1811-20.
219. Mosher DF, Johnson RB. Specificity of fibronectin-fibrin cross-linking. Ann NY Acad Sci 1983; 408: 583-94.
220. a acceptor site in bovine plasma fibronectin. FEBS Lett 1981; 127: 174-8.
221. Fésüs L, Mestis ML, Muszbek L, et al. Transglutaminase-sensitive glutamine residues of human plasma fibronectin revealed by studying its proteolytic fragments. Eur J Biochem 1986; 154: 371-4.
222. Procyk R, Adamson L, Block M, et al. Factor XIII catalyzed formation of fibrinogen-fibronectin oligomers - a thiol enhanced process. Thromb Res 1985; 40: 833-52.
223. Procyk R, Blombäck B. Factor XIII-induced cross-linking in solutions of fibrinogen and fibronectin. Biochim Biophys Acta 1988; 967: 304-13.
224. Mosher DF, Schad PE Kleinman HK. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa. J Clin Invest 1979; 64: 781-7.
225. Keski-Oja J, Mosher DF Vaheri A. Cross-linking of major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell 1976; 9: 29-35.
226. Barry ELR, Mosher FD. Factor XIII cross-linking of fibronectin at cellular matrix assembly sites. J Biol Chem 1988; 263: 10464-9.
227. Barry ELR, Mosher FD. FXIIIa-mediated cross-linking of fibronectin in fibroblast cell layers. Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments. J Biol Chem 1989; 264: 4179-85.
228. Soria A, Soria C Boulard C. Fibrin stabilizing factor (F XIII) and collagen polymerization Experientia 1975; 31: 1355-7.
229. Sane DC, Moser TL, Pippen AMM, et al. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 1988; 157: 115-20.
230. Skorstengaard K, Halkier T, Højrup P, et al. Sequence location of a putative transglutaminase cross-linking site in human vitronectin. FEBS Lett 1990; 262: 269-74.
231. Prince CW, Dickie D Krumdieck CL. Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem Biophys Res Commun 1991; 177: 1205-10.
232. Martin MT, Lefebvre F, Rabaud M, et al. Biochemical study of adduct synthesis between fibrin monomers and elastin. Biomaterials 1988; 9: 519-24.
233. Hada M, Kato M, Ikematsu S, et al. Possible cross-linking of factor VIII related antigen to fibrin by factor XIII in delayed coagulation process. Thromb Res 1982; 25: 163-8.
234. Hada M, Kaminski M, Bockenstedt P, et al. Covalent cross-linking of von Willebrand factor to fibrin. Blood 1986; 68: 95-101.
235. Bockenstedt P, McDonagh J Handin RI. Binding and covalent cross-linking of purified von Willebrand factor to native monomeric collagen. J Clin Invest 1986; 78: 551-6.
236. Bale MD, Westrick LG Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem 1985; 260: 7502-8.
237. Bale MD, Mosher DF. Thrombospondin is a substrate for blood coagulation factor XIIIa. Biochemistry 1986; 25: 5667-73.
238. Lynch GW, Slayter HS, Miller BE, et al. Characterization of thrombospondin as a substrate for factor XIII transglutaminase. J Biol Chem 1987; 262: 1772-8.
239. Cohen I, Young-Bandala L, Blankenberg TA, et al. Fibrinoligase-catalyzed cross-linking of myosin from platelet and skeletal muscle. Arch Biochem Biophys 1979; 192: 100-11.
240. Cohen I, Blankenberg TA, Borden D, et al. Factor XIIIa-catalyzed cross-linking of platelet and muscle actin. Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-75.
241. Horváth AR, Asijee GM Muszbek L. Cytoskeletal assembly and vinculin-cytoskeleton interaction in different phases of the activation of bovine platelets. Cell Motil Cytoskel 1992; 21: 123-31.
242. Asijee GM, Muszbek L, Kappelmayer J, et al. Platelet vinculin: a substrate of activated factor XIII. Biochim Biophys Acta 1988; 954: 303-8.
243. Mellanby J, Pratt CLG. Calcium and blood coagulation. Proc. Roy. Soc. B. 1939; 128: 201-13.
244. Hartert H. Rheo-stimulation: a new method for the assay of clotting process and factor XIII. A preliminary report. Biorheology 1974; 11: 355-60.
245. Shen LL, Hermans J, McDonagh J, et al. Effects of calcium ions and covalent cross-linking on formation and elasticity of fibrin gels. Thromb Res 1975; 6: 255-65.
246. Gelman RA, Gladner JA Nossal R. Rigidity of fibrin gels as measured by quasielastic light scattering. Biopolymers 1980; 19: 1259-70.
247. Shen LL, Lóránd L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with purified zymogen. J Clin Invest 1983; 71: 1336-41.
248. Gladner JA, Nossel R. Effects of cross-linking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30: 273-88.
249. Kamykowski GW, Mosher DF, Lóránd L, et al. Modification of shear modulus and creep compliance of fibrin clots by fibronectin. Biophys Chem 1981; 13: 25-8.
250. Chou TW, Mclntire LW Petersen DM. Importance of plasma fibronectin in determining PFP and PRP clot mechanical properties. Thromb Res 1983; 29: 243-8.
251. Carr ME, Gabriel DA McDonagh J. Influence of factor XIII and fibronectin on fiber size and density in thrombin-induced fibrin gels. J Lab Clin Med 1987; 110: 747-52.
252. Lóránd L, Jacobsen A. Accelerated lysis of blood clots. Nature (London) 1962; 195: 911-2.
253. Gormsen J, Fletcher AP, Alkjaersig N, et al. Enzymatic lysis of plasma clots: the influence of fibrin stabilization on lysis rates. Arch Biochem Biophys 1967; 120: 654-65.
254. Henderson KW, Nussbaum M. The mechanism of enhanced streptokinase induced clot lysis following in vitro factor XIII inactivations. Br J Haematol 1969; 17: 445-53.
255. McDonagh RP, McDonagh J Duckert F. The influence of fibrin cross-linking on the kinetics of urokinase-induced clot lysis. Br J Haematol 1971; 21: 323-32.
256. Schwartz ML, Pizzo SV, Hill RI, et al. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest 1971; 50: 1506-13.
257. Gaffney PJ, Whitaker AN. Fibrin cross-links and lysis rates. Thromb Res 1979; 14: 85-94.
258. Jansen JWCM, Haverkate F, Koopman J, et al. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171-5.
259. Leidy EM, Stern AM, Friedman PA, et al. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res 1990; 59: 15-26.
260. Shebuski RJ, Sitko GR, Claremon DA, et al. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990; 75: 1455-9.
261. Haverkate F. Lysis of cross-linked and non-cross-linked purified fibrin. Thromb Diath Haemorrh 1975; 34: 584-5.
262. 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
263. 2-plasmin inhibitor. Blood 1985; 66: 157-60.
264. 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences. Blood Coag Fibrinolysis 1993; 4: 869-75.
265. Francis CW. Marder VJ. Increased resistance to plasmic degradation of fibrin with highly cross-linked α-polymer chains formed at high factor XIII concentrations. Blood 1988; 71: 1361-5.
266. Francis CW, Marder VJ. Rapid formation of large molecular weight α-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest 1987; 80: 1459-65.
267. Sakata Y, Mimuro J Aoki N. Differential binding of plasminogen to cross-linked and non-cross-linked fibrin: its significance in hemostatic defect in factor XIII deficiency. Blood 1984; 63: 1393-401.
268. 2-antiplasmin to fibrin. Thromb Haemost 1992; 68: 315-20.
269. 2-plasmin inhibitor cross-linked to fibrin. Thromb Haemost 1993; 70: 376.
270. 2-antiplasmin by platelets. Thromb Haemost 1995; accepted.
271. Kreager JA, Devine DV Greenberg CS. Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets. Thromb Haemost 1988; 60: 88-93.
272. Devine DV, Andestad G, Nugent D, et al. Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease. Arterioscler Thromb 1993; 13: 857-62.
273. Ádány R, Kappelmayer J, Berényi E, et al. Factors of the extrinsic pathway of blood coagulation in tumor associated macrophages. Thrombos Haemost 1989; 62: 850-55.
274. Constantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 65: 406-14.
275. Dvorak HF, Senger DR Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metast Rev 1983; 2: 41-73.
276. Ádány R, Szegedi A, Ablin RJ, et al. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost 1988; 60: 293-7.
277. Muszbek L, Ádány R. Intratumoral fibrin stabilization. In: Nigam SK, McBrien DCH, Slater TF, eds. Lipid peroxidation and cancer. Pp. 339-49. Berlin: Springer Verlag, 1988.
278. Dvorak HF, Harvey S McDonagh J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 1984; 44: 3348-54.
279. Zacharski LR, Brown FE, Memoli WA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immun Immunopathol 1992; 63: 155-62.
280. Chignier E, Baguet J, Dessapt B, et al. Skin healing and fibrin stabilization factor blood levels in rabbit fetus. J Surg Res 1981; 31: 415-32.
281. Marktl W, Rundas B. The effect of factor XIII on wound granulation in the rat. Thromb Diath Haemorrh 1974; 32: 578-81.
282. Knoche H, Schmitt G. Autoradiographische Untersuchungen über den Einfluss des Factors XIII auf die Wundheilung im Tierexperiment. Arzn Forsch 1976; 26: 547-51.
283. Gierhake FW, Volkman W, Becker W, et al. Factor XIII concentration and wound healing. German Med Month 1970; 15: 721-5.
284. Gierhake FW, Papastavrou N, Zimmermann K, et al. The prophylaxis of post-operative disturbances of wound healing with factor XIII substitution (result of a double-blind study). Dtsch Med Wochenschr 1974; 99: 1004-9.
285. Mishima Y, Nagao F, Ishibiki K, et al. Faktor XIII in der Behandlung post-operative-theratierefrakturer Wundheilungsstörungen. Chirurg 1984; 55: 803-8.
286. Isogai N, Ueda Y, Kurozumi N, et al. Wound healing at the site of microvascular anastomosis: fibrin-stabilizing factor XIII administration and its effects. Microsurgery 1990; 11: 40-6.
287. Claes L, Burri C, Gerngross H, et al. Die Beschlennigung der Frakturheilung durch Faktor XIII. Helv Chir Acta 1984; 51: 209-12.
288. Claes L, Burri C, Gerngross H., et al. Bone healing stimulated by plasma FXIII. Acta Orthop Scand 1985; 56: 57-62.
289. Gerngross H, Claes L. Successful treatment of pseudoarthrosis with human placental factor XIII concentrate. In: McDonagh J, Seitz R, Egbring R, eds. Factor XIII: second international conference. P. 271. Stuttgart: Schattauer, 1993.
290. Beck E, Duckert F Ernst M. The influence of fibrin stabilizing factor on the growth of fibroblasts in vitro and wound healing. Thromb Diath Haemorrh 1961; 6: 485-91.
291. Ueyama M, Urayama T. The role of factor XIII in fibroblast proliferation. Jpn J Exp Med 1978; 48: 135-42.
292. Bruhn HD, Pohl J. Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin. Klin Wochenscr 1981; 59: 145-6.
293. Bruhn HD, Bernmeier R, Broers H, et al. Regulation der Fibroblasten- und Endothelzellenproliferation durch Thrombin, Factor XIII und Fibronectin. In: Verhandlungsbericht der 25. Tagung der deutschen Arbeitgemeinschaft für Blutgerinnungsforschung. Pp. 257-65. Stuttgart: Schattauer, 1981.
294. Bruhn HD. Growth regulation of vessel wall cells and of tumor cells by thrombin, factor XIII and fibronectin. Thromb Haemost 1981; 46: 762.
295. Bruhn HD, Zurborn KH. Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983; 46: 85-8.
296. Paye M, Nusgens BV Lapière CM. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasis 1989; 19: 274-83.
297. Ádány R, Fodor F, Molnár P, et al. Increased density of histiocytes in uterine leiomyomas. Int J Gynecol Pathol 1990; 9: 137-44.
298. Bergsen M, Weller M, Heimann K, et al. Nachweis von Gerinnungsfaktor XIII im Glaskörper und periretinalen Membranen bei proliferativen Netzhauterkrankungen. Forschr Opthalmol 1990; 87: 279-82.
299. Weller M, Bergsen M, Heinmann K, et al. Blood coagulation factor XIII contributes to the development of traction retinal detachment. Acta Opthalmol 1990; 68: 246-52.
300. Kang Y, Hashimoto N, Kikuchi H, et al. Effects of blood coagulation factor XIII on the development of experimental cerebral aneurysms in rats. J Neurosurg 1990; 73: 242-7.
301. Kasai S, Kunimoto T Nitta K. Cross-linking of fibrin by activated factor XIII stimulates attachment, morphological changes and proliferation of fibroblasts. Biomed Res 1983; 4: 155-60.
302. Herter T, Anaguostopoulos-Svchleep J Windman D. The influence of factor XIII on the fibrosing of a nerve anastomosis in the rat. Res Exp Med 1989; 189: 25-32.
303. Toida M, Watanabe F, Tsai CS, et al. Factor XIIIa-containing cells and fibrosis in oral and maxillofacial lesions: an immunohistochemical study. Oral Surg Oral Med Oral Pathol 1989; 68: 293-9.
304. Grinnel F, Feld M Minter D. Fibroblast adhesion to fibrinogen and fibrin substrates: requirement for cold insoluble globulin (plasma fibronectin). Cell 1980; 19: 517-25.
305. Lanir N, Ciano PS, Van de Water L, et al. Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. J Immunol 1988; 140: 2340-9.
306. Paye M, Lapière CM. The lack of attachment of transformed embryonic lung epithelial cells to collagen I is corrected by fibronectin and factor XIII. J Cell Sci 1986; 86: 95-107.
307. Leibovich SJ, Ross R. The role of macrophages in wound repair. A study with hydrocortisone and antimacrophage serum. Amer J Pathol 1975; 78: 71-100.
308. Glynn LE. Tissue repair and regeneration. New York: Raven Press, 1985.
309. Okamoto M, Yamamoto T, Matsubara S, et al. Factor XIII-dependent generation of 5th complement component (C5)-derived monocyte chemotactic factor coinciding with plasma clotting. Biochim Biophys Acta 1992; 1138: 53-61.
310. Tidrick RT, Warner ED. Fibrin fixation of skin transplants. Surgery 1944; 15: 90-5.
311. Fisher S, Rikover M Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood 1966; 28: 34-9.
312. Rodeghiero F, Castaman GC, Di Bona E, et al. Successful pregnancy in women with congenital factor XIII deficiency. Blut 1987; 55: 45-8.
313. Kobayashi T, Terao T, Kojima T, et al. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 1990; 29: 235-8.
314. Halkiel T, Magnusson S. Contact activation of blood coagulation is inhibited by plasma factor XIII b-chain. Thromb Res 1988; 51: 313-24.
315. Sixma JJ, Van den Berg A, Schiphorst M, et al. Immunocytochemical localization of albumin and factor XIII in thin cryo sections of human blood platelets. Thromb Haemost 1984; 51: 388-91.
316. Joist JH, Niewiarowski S. Retention of platelet fibrin stabilizing factor during the platelet release reaction and clot retraction. Thromb Diath Haemorrh 1973; 29: 679-83.
317. Holme PA, Brosstadt F Solum NO. The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation. Thromb Haemost 1993; 70: 681-6.
318. Kasahara K, Takagi J, Sekiya F, et al. "A" subunit of factor XIII is present on bovine platelet membrane and mediates collagen-induced platelet activation. Thromb Res 1988; 50: 25363.
319. Saito Y, Imada T, Takagi J, et al. Platelet factor XIII. The collagen receptor? J Biol Chem 1986; 261: 1355-58.
320. Aihara M, Sawada Y, Takami H, et al. Factor XIII is not involved in human platelet-collagen interaction. Tohoku J Exp Med 1989; 159: 37-44.
321. Ozsoylu S, Hicsonmez G. Platelet aggregation in congenital factor XIII deficiency. Acta Haematol 1976; 56: 314-7.
322. Rao KMK, Newcomb TF. Clot retraction in a factor XIII free system. Scand J Haematol 1980; 24: 142-48.
323. Zhu Y, Tass L, Lane W, et al. Specific binding of the transglutaminase, platelet factor XIII, to HSP27. J Biol Chem 1994; 269: 22379-84.
324. Mendelsohn ME, Zhu Y O'Neill S. The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor related 27-kDa heat shock protein. Proc Natl Acad Sci USA 1991; 88: 11212-16.
325. Zhu Y, O'Neill S Mendelsohn ME. HSP27, a thrombin-activated phosphoprotein, translocates to the cytoskeleton following human platelet activation. Circulation 1992; 86(Suppl I): 739a.
326. Muszbek L, Ádány R, Lopaciuk S, et al. Possible role of factor XIII subunit a in phagocytosis by monocytes. Haematol Rev 1986; 1: 120a.
327. Kávai M, Ádány R, Pásti G, et al. Marker profile, enzyme activity, and function of a human myelomonocytic leukemia cell line. Cell Immunol 1992; 139: 531-40.
328. Yee VC, Pedersen LC, Bishop PD, et al. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res 1995; 78: 389-97.